🔗 Share this article

Given that the United States proceeds with historic revisions to its vaccine schedules, one figure appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines throughout the pandemic and has concentrated on alleged deaths following Covid vaccination in her short tenure at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Health officials had intended to unveil radical revisions to the childhood immunization program in December, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of alignment with a large portion of the global community with little proof for improved outcomes. The announcement has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting some childhood vaccine recommendations in the US in order to be more like Denmark, a country with nationalized medicine and a number of inhabitants approximately the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the domain of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

The appointee has no apparent background in drug development, regulation or administrative roles, which has been customary for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have the necessary background” for leading the CDER, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “grasp laws and regulations and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who headed CBER have had.”

The drug center has an immense workload at the agency, Woodcock pointed out.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and all of those must be managed,” she explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership element to the position, which supervises in excess of 5,000 staff members. “It’s a massive leadership role, if you do it right,” Woodcock said.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's credentials and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a spokesperson said that the “inquiries rely on flawed presumptions”.

“Her resume is consistent with the responsibilities of her role,” the representative said, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a disputed expedited drug-approval program that apparently worried her predecessors. “By what process are these therapies being picked for this expedited pathway? Who makes the decisions?” Dr. Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards less stringent oversight of all drugs, aside from shots.”

Documented Track Record on Vaccines

With vaccines, Høeg has a more documented, if troubling, history, critics said. She authored a study using unconfirmed public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current government encompassed changing guidelines for novel immunizations and discontinuing “non-essential” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has according to sources proposed preventing young men from obtaining COVID-19 vaccinations.

“She is an complete ideologue who starts off with her preconceived notions and tailors the evidence to retrofit the evidence in a extremely disingenuous, fraudulent fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other dissenters, {like|